SynergyMed Cancer Treatment Technology

Successful studies on mice and dogs
Aim to enter veterinary market by Q3 2025. Targeting FDA approval & human commercialization by 2026
$0.5 Billion projected revenue within 5 years (not guaranteed)
Received awards and recognitions from 6 national and international startup competitions and events
Patent-pending technology
Available CPT Codes for reimbursement by Medicare and commercial insurances
Commercial product near completion and certification
Building collaborations with leading U.S. institutions (Tufts, Harvard, ...)

Anan Copty CEO25+ years of technical & leadership experiences,
RMD: Radiation Monitoring Devices, Intel: Biochips, Harvard Medical School: MRI, Yahya Dajani VP of Business DevelopmentMedical Technology Entrepreneur. Co-founded NCA Monitoring Technologies & D&O LLC
ADNOC Oil Company
Corporate Planning, Finance, Performance, and Business Development, Daniel Kacher, Ph.D.Director of Clinical Studies and Product DevelopmentPh.D. in Biomedical Engineering
25 years at Brigham and Women’s Hospital, Robert Roy, MBA, BSEE/BSMEVP of Marketing, Sales35+ years of senior-level management in medical device companies, Mimi Copty, MHACOO25+ years of project management & leadership experiences in health organizations in the US and internationally